Literature DB >> 24899965

Normal Physiologic and Benign Foci with F-18 FDG Avidity on PET/CT in Patients with Breast Cancer.

Soon-Ah Park1, Kwang-Man Lee2, UnJong Choi2, Hun Soo Kim3, Hye-Won Kim4, Jeong Hoon Song5.   

Abstract

PURPOSE: The aim of this study was to evaluate the physiologic and benign F-18 fluorodeoxyglucose (FDG) avid foci in patients with breast cancer.
METHODS: On 309 F-18 FDG PET/CT scans of 241 women with breast cancer, the hypermetabolic lesions compared with the surrounding normal region were evaluated retrospectively. Available reports of other relevant radiological imaging, medical records, and follow-up PET/CT were reviewed for explanations of the abnormal uptake.
RESULTS: Among the 70 physiologic foci, muscular uptake of the lower neck following the surgical and/or radiation therapy of ipsilateral breast (29%), hypermetabolic ovaries (16%) and uterine (10%) uptake during the ovulatory and menstrual phases during the normal menstrual cycle were identified, and also hypermetabolic brown fat in cold-induced thermogenesis (7%), non-specific bowel uptake (35%) were observed. Among the 147 benign lesions, sequelae of the chest wall and breasts following surgical and/or radiation therapy, were often observed (27%). Hypermetabolic thyroid glands were noted as adenomas and chronic thyroiditis (18%). Reactive hyperplasia of cervical or mediastinal lymph nodes (32%), degenerative osteoarthritis and healed fractures (15%), hypermetabolic benign lung lesions (6%) were observed.
CONCLUSION: Altered physiologic and benign F-18 FDG uptake in the lower cervical muscle and chest wall following ipsilateral breast surgery or radiotherapy were common, and also normal physiologic uptake in ovary and uterus, brown fat, thyroid were considered as predominant findings in women patients with breast cancer. Knowledge of these findings might aid in the interpretation of FDG PET/CT in patients with breast cancer.

Entities:  

Keywords:  Benign; Breast; Carcinoma; F-18 fluorodeoxyglucose; FDG; Physiologic

Year:  2010        PMID: 24899965      PMCID: PMC4042921          DOI: 10.1007/s13139-010-0055-7

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  23 in total

1.  Positron emission tomography and PET CT of the head and neck: FDG uptake in normal anatomy, in benign lesions, and in changes resulting from treatment.

Authors:  Gerhard W Goerres; Gustav K Von Schulthess; Thomas F Hany
Journal:  AJR Am J Roentgenol       Date:  2002-11       Impact factor: 3.959

Review 2.  A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases.

Authors:  Carmen R Isasi; Renee M Moadel; M Donald Blaufox
Journal:  Breast Cancer Res Treat       Date:  2005-03       Impact factor: 4.872

Review 3.  Thermogenesis in brown adipose tissue as an energy buffer. Implications for obesity.

Authors:  J Himms-Hagen
Journal:  N Engl J Med       Date:  1984-12-13       Impact factor: 91.245

Review 4.  Evolving role of positron emission tomography in breast cancer imaging.

Authors:  William B Eubank; David A Mankoff
Journal:  Semin Nucl Med       Date:  2005-04       Impact factor: 4.446

Review 5.  PET imaging in oncology.

Authors:  R Bar-Shalom; A Y Valdivia; M D Blaufox
Journal:  Semin Nucl Med       Date:  2000-07       Impact factor: 4.446

Review 6.  Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation.

Authors:  G J Cook; I Fogelman; M N Maisey
Journal:  Semin Nucl Med       Date:  1996-10       Impact factor: 4.446

Review 7.  Advantages and limitations of FDG PET in the follow-up of breast cancer.

Authors:  Peter Lind; Isabel Igerc; Thomas Beyer; Peter Reinprecht; Klaus Hausegger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-15       Impact factor: 9.236

8.  Determination of indication for sentinel lymph node biopsy in clinical node-negative breast cancer using preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging.

Authors:  Naruto Taira; Shozo Ohsumi; Daisuke Takabatake; Fumikata Hara; Seiki Takashima; Kenjiro Aogi; Shigemitsu Takashima; Takeshi Inoue; Shigenori Sugata; Rieko Nishimura
Journal:  Jpn J Clin Oncol       Date:  2008-11-08       Impact factor: 3.019

9.  Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT.

Authors:  Hedva Lerman; Ur Metser; Dan Grisaru; Ami Fishman; Gennady Lievshitz; Einat Even-Sapir
Journal:  J Nucl Med       Date:  2004-02       Impact factor: 10.057

10.  Brown adipose tissue: a factor to consider in symmetrical tracer uptake in the neck and upper chest region.

Authors:  Thomas F Hany; Esmaiel Gharehpapagh; Ehab M Kamel; Alfred Buck; Jean Himms-Hagen; Gustav K von Schulthess
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-08-08       Impact factor: 9.236

View more
  3 in total

1.  What are the Best Ways to Reduce the False-positive Rate of 18F-FDG PET/CT in Patients with Breast Cancer?

Authors:  Laura Evangelista; Zora Baretta; Lorenzo Vinante; Guido Sotti
Journal:  Nucl Med Mol Imaging       Date:  2011-01-05

2.  Diagnostic clue of nodular fasciitis mimicking metastasis in papillary thyroid cancer, mismatching findings on 18F-FDG PET/CT and 123I whole body scan: A case report.

Authors:  Minjung Seo; Misung Kim; Eun Sook Kim; Hongbo Sim; Sungmin Jun; Seol Hoon Park
Journal:  Oncol Lett       Date:  2017-05-17       Impact factor: 2.967

3.  Detection of distant metastases in patients with locally advanced breast cancer: role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging with computed tomography scans.

Authors:  Almir Galvão Vieira Bitencourt; Wesley Pereira Andrade; Rodrigo Rodrigues da Cunha; Jorge Luis Fonseca de Acioli Conrado; Eduardo Nóbrega Pereira Lima; Paula Nicole Vieira Pinto Barbosa; Rubens Chojniak
Journal:  Radiol Bras       Date:  2017 Jul-Aug
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.